We are pleased to report that FY15 has been a productive and positive year for Regeneus Ltd (ASX:RGS). We have achieved a number of significant research and development, clinical and business milestones that have put the company in a good position to unlock value in our regenerative medicine technology and clinical assets in FY16 and beyond.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced today interim trial results showing that its allogeneic "off-the-shelf" stem cell therapy, CryoShot, has positive results on early orthopaedic developmental disease in Yearling Thoroughbreds and compares favourably against the use of conventional therapies like corticosteroids.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today that it had entered into an agreement with one of the world's top 5 animal health companies to partner the development and commercialisation of CryoShot Canine.
Rhinomed (ASX:RNO) has had a strong first quarter of the financial year with positive traction across its consumer health and clinical businesses.
Compumedics Limited (ASX:CMP) is a leading global, innovative developer and manufacturer of medical devices.
The four patients who took part in Living Cell Technologies Limited's (ASX:LCT) (OTCMKTS:LVCLY) Phase I/IIa clinical study of NTCELL(R) for Parkinson's disease have all reached the milestone of 42 weeks post-implant. All four patients remain well, and there are no safety concerns.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the first patient has been enrolled and safely treated in the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.
